fig1

Figure 1. Unique benefits of plasma HPV ctDNA monitoring for survivorship care of veterans with HPV-related OPSCC. 1. A biologically distinct population: enhanced utility of plasma HPV ctDNA monitoring in recurrence prediction for intermediate-risk disease; 2. Broadened geographic accessibility: ability to surveil a greater number of patients in wide catchment area via “surveillance at a distance” paradigm; 3. Reduction of logistical barriers and enhanced patient satisfaction: reduction of in-person visits and imaging afforded by plasma HPV ctDNA monitoring attenuates the burden of transportation, lodging, and lost work time; 4. Reduced costs for VHA and veterans alike: plasma HPV ctDNA monitoring may allow economic triaging of patients who need in-person care; 5. Equal opportunities for treatment and surveillance de-intensification via clinical trials. Created in BioRender.com.